Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Net debt is broadly in line with December 2020 as FCF was offset by the annual dividend and share buybacks USD bn -24.5 +0.2 -2.9 0.4 -24.3 T -7.4 -0.2 10.3 Dec 31, 2020 Dividends M&A transactions Free Cash Flow Treasury share transactions, net Others Sep 30, 2021 49 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine

View entire presentation